Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trialMassimiliano Fabbiani, Nicoletta Ciccarelli, Eugenia Quirós-Roldán et al.|Journal of Antimicrobial Chemotherapy|2018Cited by 33
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trialFrancesca Lombardi, Simone Belmonti, Eugenia Quirós-Roldán et al.|Journal of Antimicrobial Chemotherapy|2017Cited by 31